No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
EXAS240517P60000
- 2.25
- +0.55+32.35%
15min DelayClose May 7 16:00 ET
2.25High1.80Low
1.80Open1.70Pre Close2 Volume1.01K Open Interest60.00Strike Price405.00Turnover74.76%IV-6.04%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry2.25Time Value100Contract SizeAmericanOptions Type-0.3973Delta0.0509Gamma26.70Leverage Ratio-0.1471Theta-0.0067Rho-10.61Eff Leverage0.0391Vega
Intraday
- 5D
- 1D
News
Exact Sciences: Maintaining Market Dominance With Cologuard Amid Emerging Competition
Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening With Multiple Data Presentations at DDW 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the company will present six abstracts on strategies a
LabCorp Partner Geneoscopy Wins FDA Approval of Colorectal Cancer Test ColoSense
Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report
Earnings reports and a dovish stance from the Federal Reserve lifted stocks last week. Major indices reacted positively, particularly to earnings from high-profile companies that hold significant weig
Earnings Week Ahead: Disney, Palantir, Shopify, Uber, Plug Power and More
There's No Escaping Exact Sciences Corporation's (NASDAQ:EXAS) Muted Revenues
With a price-to-sales (or "P/S") ratio of 4.4x Exact Sciences Corporation (NASDAQ:EXAS) may be sending very bullish signals at the moment, given that almost half of all the Biotechs companies in the U
Comments
Exact Sciences' progress has failed to meet high market expectations, yet its consistent revenue growth suggests it may be worth further investigation. The company's performance has underperformed the broader market, which gained around 31%.
2
The company's strained balance sheet and lack of EBIT level profitability heighten risk. Its debt management and growth rate are key concerns, with faster growth expected from unprofitable firms.
Exact Sciences' low P/S ratio is due to its poor revenue outlook. Investors foresee limited growth, thus are only willing to pay less for the stock, making a strong share price rise unlikely.
Exact Sciences' growth rate is somewhat slow, showing a 20% rise in revenue while lacking profitability at an EBIT level. Considerable liabilities and negative EBIT results make its financial status seem precarious and risky.
Read more